Artidis NEO-Match Test Pancreatic Cancer NCT07542041
Summary
The NIH has registered a new prospective single-arm clinical study (NCT07542041) on ClinicalTrials.gov evaluating the NEO-Match test, which uses ARTIDIS nanomechanical profiling technology, in patients with suspected pancreatic cancer undergoing biopsy. The study will assess the test's ability to predict neoadjuvant treatment response and detect malignant pancreatic lesions compared to standard histopathology. Participants will be followed every 3 months for up to 2 years; the study does not alter standard-of-care treatment.
This registration is informational and does not impose compliance obligations on regulated entities. Healthcare providers conducting pancreatic cancer trials or using ARTIDIS technology should note the study's inclusion criteria, follow-up schedule, and comparator methodology for awareness of emerging predictive tools in this indication.
What changed
The NIH has registered NCT07542041, a prospective clinical study evaluating the NEO-Match test based on ARTIDIS nanomechanical profiling technology, in patients with suspected pancreatic cancer. The study aims to assess the test's predictive value for neoadjuvant treatment response and its diagnostic accuracy compared to standard histopathological assessment.
This registration is an informational entry on ClinicalTrials.gov and does not create compliance obligations. Clinical investigators, oncology trial sponsors, and healthcare providers should review the study's inclusion criteria and follow-up protocol for awareness of emerging biomarker technologies in pancreatic cancer diagnostics, but no regulatory action is required.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens
N/A NCT07542041 Kind: NA Apr 21, 2026
Abstract
The goal of this clinical study is to evaluate whether the NEO-Match® test, based on ARTIDIS nanomechanical profiling technology, can help predict treatment outcomes and improve clinical decision-making in patients with suspected pancreatic cancer undergoing biopsy.
The main questions this study aims to answer are:
- Can the NEO-Match® test predict how patients respond to neoadjuvant (pre-surgical) treatment for pancreatic cancer?
- How well does the NEO-Match® test detect malignant pancreatic lesions compared to standard histopathological assessment?
This is a prospective, single-arm study. Researchers will compare results from the NEO-Match® test with standard clinical outcomes, imaging findings, and pathology results to evaluate its predictive and diagnostic performance.
Participants will:
- Undergo a standard-of-care pancreatic biopsy or surgical procedure
- Provide an additional biopsy sample for research analysis using the ARTIDIS ART-1 device
- Continue to receive standard treatment and care, which is not influenced by the study
- Have clinical data, imaging results, and treatment outcomes collected
- Be followed every 3 months for up to 2 years
The study does not involve experimental treatment or changes to standard medical care. The information collected may help improve future diagnosis, prognosis, and treatment selection for patients with pancreatic cancer.
Conditions: Pancreatic Cancer, Pancreatic Neoplasms, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Lesions Located at the Body or the Tail
Interventions: ARTIDIS ART-1 Device
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.